

Upcoming Internal and External Funding Opportunities in Cancer Research

Click here to view the opportunities online and bookmark the Siteman "Funding for Faculty" page.



Opportunities specific to early career applicants are noted in green below.

Deadline	Funding Opportunity	Sponsor	Max Amount and Period	RFP Snapshot Description	Eligibility Notes	Applicant Notes
June 30, 2024 - 10:59PM CST EARLY CAREER SPECIFIC OPPORTUNITY	Siteman Trainee Travel Awards	Siteman Cancer Center	\$1,500	<i>The Siteman Trainee Travel Award supports scholars in career development related to cancer research or cancer health disparities research by providing reimbursement (i.e. registration, airfare, hotel, etc.) to present research at conferences and/or attend workshops/trainings. Scholars who are Underrepresented in Medicine (URiM) and/or women are strongly encouraged to apply.</i>	Trainee must be affiliated with Siteman Cancer Center, Washington University, BJC, Children's Hospital, SLU, or University of Missouri. All cancer related research and cancer disparities research trainees encouraged to apply. Priority given to NCI affiliated trainees. Must be a pre-doctoral trainee (doctoral student), postdoctoral trainee, research fellow, or early career faculty (instructor or assistant professor who has not yet held an R01 award). Conference location must be within the domestic USA; includes Canada, Mexico, and US Territories. This award may be used as a supplement to other scholarships, but may not be used to duplicate other resources.	N/A
July 1, 2024 - Noon CST EARLY CAREER SPECIFIC OPPORTUNITY	AACR-Novocure Career Development Award for Cancer Research	AACR	\$300,000 over 3 years	<i>This grant represents a joint effort to promote and support early-career investigators who are conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage early-career investigators to enter the TTFields research field. The In vitro system (which will be provided by Novocure, if needed), must be included in the experimental design.</i>	Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Applicants must hold a faculty position with the title of Instructor, Research Assistant Professor, or Assistant Professor. They must have received their first faculty position with the past six years, i.e. must have begun their appointment on December 1, 2018 or later.	Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
July 1, 2024 - Noon CST EARLY CAREER SPECIFIC OPPORTUNITY	AACR-Novocure Cancer Research Grants	AACR	\$350,000 over 3 years	<i>This grant represents a joint effort to promote and support independent investigators who are currently conducting innovative research focused on Tumor Treating Fields (TTFields; intermediate frequency, low intensity, alternating electric fields that disrupt cell division in cancer cells) as well as to encourage independent investigators to enter the TTFields research field. The In vitro system (which will be provided by Novocure, if needed), must be included in the experimental design.</i>	Applicants must have a doctoral degree (PhD, MD, MD/PhD, or equivalent) in a related field and not currently be a candidate for a further doctoral degree. Current AACR Grantees may apply if their current grant ends before the start of the grant term of this funding opportunity i.e., December 1, 2024, and must be up to date with all reporting requirements to be considered eligible. Applicants must also be AACR Active members in good standing.	Application Assistance: Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.

<p>July 8, 2024 - 3PM CST</p>	<p>Damon Runyon-Rachleff Innovation Award Stage 1</p>	<p>Damon Runyon Cancer Research Foundation</p>	<p>\$400,000 over 2 years</p>	<p><i>The Damon Runyon-Rachleff Innovation Award is designed to provide support for the next generation of exceptionally creative thinkers with "high-risk/high-reward" ideas that have the potential to significantly impact our understanding of and/or approaches to the prevention, diagnosis or treatment of cancer. The Innovation Award is specifically designed to provide funding to extraordinary early career researchers who have an innovative new idea but lack sufficient preliminary data to obtain traditional funding. It is not designed to fund incremental advances. The research supported by the award must be novel, exceptionally creative and, if successful, have the strong potential for high impact in the cancer field.</i></p>	<p>Applicants (including non-U.S. citizens) must be conducting independent research at a U.S. research institution. The applicant must have received an MD, DO, PhD, or MD/PhD degree(s) from an accredited institution. Basic and translational/clinical projects will be considered. Applications will be accepted from all scientific disciplines provided that the proposed research meets the selection criteria.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.</p>
<p>Letter of Intent: July 9, 2024 - Noon CST</p> <p>EARLY CAREER SPECIFIC OPPORTUNITY</p>	<p>Fanconi Cancer Foundation-AACR NextGen Grant for Transformative Cancer Research</p>	<p>AACR</p>	<p>\$450,000 over 3 years</p>	<p><i>This grant mechanism is intended to promote and support creative, paradigm-shifting cancer research that may not be funded through conventional channels. It is expected that this grant will catalyze significant scientific discoveries and help talented young investigators gain scientific independence. Fanconi anemia (FA) is a rare genetic disease caused by loss-of-function mutations in any one of 22 FA genes, which are integral to the FA/BRCA DNA repair pathway and include the breast cancer susceptibility genes BRCA1 and BRCA2. The disease is marked by congenital abnormalities, bone marrow failure, and a high risk of solid tumors and leukemia. Individuals with FA have a hundreds- to thousands-fold increased risk of developing squamous cell cancers of the head and neck, esophagus, and anogenital regions, in addition to an elevated risk for other solid tumors.</i></p>	<p>Applicants must have a doctoral degree in a related field and not currently be a candidate for a further doctoral degree. Applicants must currently hold a tenure-eligible appointment at the rank of Assistant Professor, and they must have begun that appointment on December 1, 2021 or later. Applicants also must be AACR Active members in good standing.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.</p>
<p>WUSTL INTERNAL SELECTION: July 10, 2024 - 11:59PM CST</p> <p>EARLY CAREER SPECIFIC OPPORTUNITY</p>	<p>NEW: 2024-2025 Komen Career Catalyst Research (CCR) Grants</p>	<p>Susan G. Komen</p>	<p>\$450,000 over 3 years</p>	<p><i>This grant aims to foster promising breast cancer researchers who are in the early stages of their faculty careers by providing support for up to three years of "protected time" for research career development under the guidance of a Mentor Committee. Komen seeks to support those who will emerge as the next key leaders in the fight against breast cancer. Research projects must be hypothesis-driven, breast cancer-focused studies. They may be considered basic, translational, clinical and/or population science in nature and should align with Komen's research goals and priorities and mission to save lives from breast cancer.</i></p>	<p>Applicants must have a doctoral degree, such as MD, PhD, DrPH, DO, or equivalent. They must currently hold a full-time faculty appointment or have a formal offer letter from the Institution that confirms position and start date by the Application due date (October 9, 2024), documented by the Applicant/PI Biosketch and Letter of Institutional Support. They must not have held any faculty appointment, including non-tenure and tenure track appointments combined, for more than a total of 6 years by the Application due date (October 9, 2024), documented by the Applicant/PI Biosketch and Letter of Institutional Support. Must not currently be or have been a Principal Investigator on an existing NIH R01 grant or their equivalent as of the date of Award Notification (on or around April 15, 2025). They must devote at least 75% of full-time effort to breast cancer research. Applicants are not required to be a US citizen or permanent resident.</p>	<p><u>Internal Selection Note:</u> WUSTL is eligible to nominate up to TWO candidates for this category, if at least one of the two nominees identify as someone from groups shown to be historically minoritized and marginalized in biomedical research.</p> <p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.</p>
<p>July 15, 2024 - 3PM CST</p>	<p>NEW: Damon Runyon Dale F. Frey Award</p>	<p>Damon Runyon Cancer Research Foundation</p>	<p>\$100,000 for 1 year</p>	<p><i>At the end of the Damon Runyon Fellowship, there are often a select few who have greatly exceeded the Foundation's highest expectations. These spectacular young scientists are the most likely to make paradigm-shifting breakthroughs that transform the way we prevent, diagnose and treat cancer. To catapult their research careers—and their impact on cancer—the Foundation will make an additional investment in these exceptional individuals by selecting them as recipients of the Damon Runyon-Dale F. Frey Award for Breakthrough Scientists.</i></p>	<p>Damon Runyon Fellows are eligible to apply in the last year of their Fellowship. Currently, Damon Runyon Fellows selected in November 2020, May 2021, and February 2022 (DRG-2418-21 to DRG-2451-21, DRQ-13-22 to DRQ-15-22) are eligible to apply.</p>	<p><u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.</p>

July 15, 2024 - 10:59PM CST	Hyundai Hope on Wheels Pediatric Cancer Survivorship Collaboration Award	Hyundai Hope on Wheels	\$1M over 3 years	<i>The Survivorship Collaboration Award was developed to provide funding for collaborative research projects focused on pediatric cancer survivorship. The ultimate long-term goal is to improve the quality of life of pediatric cancer survivors. Survivorship Collaboration Awards should be translational in nature, with a clear path to directly impacting patients. Proposals will be judged based on innovation, impact, and clear, measurable and demonstrated outcomes by the end of the three-year period of support.</i>	Eligible applicants for this grant must have a doctoral degree (MD, DO, PhD), a solid track record of involvement in pediatric cancer survivorship, and must be able to commit at least 10% effort to the project. A key component of the Hyundai Survivorship Grant is the requirement for collaboration by two or more institutions, each of which must make substantial contributions to a shared project.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
July 19, 2024 - 5PM CST	NEW INTERNAL: Center for Drug Discovery QuikSTART Grant	Center for Drug Discovery and Siteman Cancer Center	\$25,000 for 1 year	<i>This award is designed to advance the translation of new discoveries in cancer disease biology into small molecule therapeutics for the benefit of patients. CDD offers a full suite of preclinical drug discovery services and know-how. Capabilities range from drug lead finding utilizing the High Throughput Screening Core to Medicinal Chemistry-driven drug lead optimization, ADME profiling, and in-vivo pharmacokinetics, furnishing drug-like molecules for proof-of-concept in</i>	The PI must have a full-time faculty appointment at Washington University (WU) at the rank of Assistant Professor or above and hold Siteman Cancer Center membership.	N/A
Letter of Intent: August 1, 2024 - 10:59PM CST	ACS Professor Awards	American Cancer Society	\$400,000 over 5 years	<i>ACS Professor awards are primarily honorific awards for individuals who have made seminal contributions in cancer research. Applicants must be at the rank of full professor and have made, and will likely continue to make, impactful contributions to change the direction of cancer research. These notable cancer research achievements could have been fundamental, preclinical, clinical, psychosocial, behavioral, health policy and/or epidemiologic in focus. Commitment and success in scientific mentoring and leadership as well as community engagement are also carefully considered.</i>	Applicants must have obtained the rank of full professor and must be ready to be spokespeople for ACS and for cancer research in general.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
August 5, 2024 - 5PM CST	Multi-sectoral Preventive Interventions that Address Social Determinants of Health in Populations that Experience Health Disparities (UG3/UH3, Clinical Trial Required)	NIH/NCI	\$4.75M over 7 years UG3 Phase - 2 years UH3 Phase - 5 years	<i>The purpose of this NOFO is to support projects to test prospective multi-sectoral preventive interventions that address social determinants of health in populations that experience health disparities. This opportunity solicits bi-phasic research projects proposed in UG3/UH3 Phased Innovation Awards Cooperative Agreement applications. Funding for the UG3 phase (phase I) will be used to demonstrate sufficient preparation, feasibility and capacity to meet foundational milestone targets specific to the work proposed. A UG3 project that meets its milestones will be administratively considered by NIH and prioritized for transition to the UH3 award (phase II). Applicants responding to this NOFO must address specific aims and milestones for both the UG3 and UH3 phases.</i>	Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Individuals from diverse backgrounds, including underrepresented racial and ethnic groups, individuals with disabilities, and women are always encouraged to apply for NIH support.	N/A
Letter of Intent: August 9, 2024 - Noon CST	NEW: GFCR - All Grant Programs	Gateway for Cancer Research	\$200,000 to \$1.5M over 2-5 years Multiple mechanisms	<i>Funding mechanisms vary from the Gateway Traditional Grant Program, the NCI/SPORE/P20 Program, Integrative Research, the Society for Integrative Oncology (SIO), and the Decentralize Clinical Trial Initiative (DCTI).</i>	See full RFA for more details.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
August 31, 2024 - 5PM CST EARLY CAREER SPECIFIC OPPORTUNITY	Elsa U. Pardee Foundation Grants	Elsa U. Pardee Foundation	No Limit for 1 Year Budget must be reasonably supported by scope of project	<i>This grant is meant to support investigators in the US proposing research directed toward identifying new treatments or cures for cancer. The Foundation funds projects for a one-year period which will allow the establishment of capabilities of new cancer researchers or new cancer approaches by established cancer researchers. It is anticipated that this early-stage funding by the Foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.</i>	Priority is given to researchers at non-profit institutions in the United States who are new to the field of cancer research, or to established research investigators examining new approaches to cancer cure. Post-docs who are on the tenure track and have a tenured mentor are eligible.	<u>Application Assistance:</u> Washington University faculty may reach out to Danny Jaschek in Medical Corporate and Foundation Relations at daniel.jaschek@wustl.edu with any questions and for assistance with reviewing/editing the proposal.

August 31, 2024 - 10:59PM CST	ACS Extramural Discovery Science Accelerator Award	American Cancer Society	\$75,000 for 1 year	<i>The intent of the Extramural Discovery Science (EDS) Accelerator Award is to support the commercialization of an ongoing cancer research project and to validate and de-risk technologies. Proposals should address key experiment(s) required to move findings toward commercialization that do not easily fit into traditional grant funding mechanisms. This mechanism is not designed to initiate new projects or develop new directions for an ongoing project. The proposal should be commercially driven with the PI having a plan to license the technology, either to an established company or a start-up if the experiment(s) are successful.</i>	Applicants must be current or former ACS awardees (including IRG pilot grant awardees), or former ACS postdoctoral fellows. Applicants may be at any career stage, provided they have a full-time faculty appointment. Applicants must be motivated to commercialize their technology.	<u>Application Assistance:</u> Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at floydg@wustl.edu with any questions and for assistance with reviewing/editing the proposal.
-------------------------------	--	-------------------------	---------------------	---	--	---

Internal Grant Resources (≤\$25) with Rolling Deadlines

Sponsor	Website	Notes
SCC BQSR Biostatistics and Qualitative Research Shared Resource	Grant Preparation Support - Free for SCC Members	N/A
WUSTL CDD Center for Drug Discovery	CDD Match Grants	Rolling Deadlines
WUSTL ICTS Institute of Clinical and Translational Sciences	Innovation Awards	Rolling Deadlines
WUSTL ICTS and Siteman Cancer Center	Just-in-Time (JIT) Core Usage Funding Program	Rolling Deadlines; Siteman Cancer Center will co-sponsor cancer-focused proposals.

OTHER FUNDING OPPORTUNITY QUICK LINKS

Be sure to check the websites below regularly for ongoing NATIONAL funding opportunities.

NEW: WUSTL Funding Database	https://research.wustl.edu/funding/finding-funding/funding-opportunity-database/
WUSTL CDI	https://implementationresearch.wustl.edu/support-your-research/funding-opportunities-2/
DOD	https://cdmrp.health.mil/funding/
NCI	https://www.cancer.gov/grants-training/grants-funding/funding-opportunities
NIH	https://grants.nih.gov/funding/index.htm

This newsletter is not fully inclusive of all available cancer-related funding.
Please be sure to consult other sources to learn of other opportunities not listed above.

[Click to view these opportunities in a web browser and bookmark the Siteman “Funding for Faculty” page.](#)